How to gain a competitive advantage in a fast-changing pharmaceutical supply ecosystem.
The global Covid-19 pandemic as well as geopolitical tensions and trade restrictions have drawn attention to profound geographical, technical, and structural shifts in pharmaceutical supply chains. Treatments are increasingly produced by highly capable contract development and manufacturing organizations (CDMOs). As new, extraordinarily sophisticated, advanced therapies (ATx) emerge to complement traditional large and small molecule treatments, this trend looks set to deepen and accelerate. Today, CDMOs are targeting an increasingly attractive business segment, in which pure play CDMOs and other market participants are taking on a growing role.Continue reading Strategy&’s 2022 Global CDMO Study of Pharmaceutical Operations